Improved Revenues Required Before CanSino Biologics Inc. (HKG:6185) Stock's 26% Jump Looks Justified
Aug 04
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedAug 15, 2025
DataAggregated Company Financials
Companies57
- 7D6.8%
- 3M76.8%
- 1Y191.0%
- YTD138.0%
The Biotech is pretty flat in the last 7 days, but RemeGen has stood out, gaining 28%. As for the the longer term, the industry is up 187% over the past 12 months. As for the next few years, earnings are expected to grow by 40% per annum.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 15 Aug 2025 | HK$1.0t | HK$63.8b | -HK$12,737,883,616.92 | 48x | -81.7x | 16.3x |
| Sun, 13 Jul 2025 | HK$788.5b | HK$63.8b | -HK$12,211,400,221.91 | 31.6x | -64.6x | 12.4x |
| Tue, 10 Jun 2025 | HK$707.0b | HK$62.2b | -HK$11,779,646,869.98 | 34.3x | -60x | 11.4x |
| Thu, 08 May 2025 | HK$562.2b | HK$61.1b | -HK$11,936,574,058.48 | 31x | -47.1x | 9.2x |
| Sat, 05 Apr 2025 | HK$539.7b | HK$58.3b | -HK$10,877,887,402.05 | 31x | -49.6x | 9.3x |
| Mon, 03 Mar 2025 | HK$443.5b | HK$52.1b | -HK$17,202,023,185.82 | 17x | -25.8x | 8.5x |
| Wed, 29 Jan 2025 | HK$356.4b | HK$52.3b | -HK$17,398,311,890.15 | 12.3x | -20.5x | 6.8x |
| Fri, 27 Dec 2024 | HK$379.1b | HK$51.8b | -HK$17,223,035,304.34 | 10.8x | -22x | 7.3x |
| Sun, 24 Nov 2024 | HK$387.3b | HK$52.3b | -HK$17,389,276,675.89 | 10.4x | -22.3x | 7.4x |
| Tue, 22 Oct 2024 | HK$400.2b | HK$52.4b | -HK$17,911,065,536.33 | 12x | -22.3x | 7.6x |
| Thu, 19 Sep 2024 | HK$379.0b | HK$52.6b | -HK$18,253,092,300.55 | 10.8x | -20.8x | 7.2x |
| Sat, 17 Aug 2024 | HK$325.6b | HK$51.0b | -HK$19,223,761,250.23 | 11.7x | -16.9x | 6.4x |
| Mon, 15 Jul 2024 | HK$329.5b | HK$49.7b | -HK$19,482,026,112.04 | 12.7x | -16.9x | 6.6x |
| Wed, 12 Jun 2024 | HK$337.8b | HK$49.7b | -HK$19,481,479,995.14 | 10.2x | -17.3x | 6.8x |
| Fri, 10 May 2024 | HK$378.8b | HK$49.9b | -HK$19,284,929,922.34 | 12.4x | -19.6x | 7.6x |
| Sun, 07 Apr 2024 | HK$331.0b | HK$49.3b | -HK$19,506,665,375.55 | 10.2x | -17x | 6.7x |
| Tue, 05 Mar 2024 | HK$352.5b | HK$47.2b | -HK$20,388,952,176.16 | 16.2x | -17.3x | 7.5x |
| Thu, 01 Feb 2024 | HK$306.2b | HK$47.3b | -HK$20,430,384,723.00 | 14.7x | -15x | 6.5x |
| Sat, 30 Dec 2023 | HK$409.4b | HK$47.3b | -HK$20,423,403,763.00 | 17.8x | -20x | 8.7x |
| Mon, 27 Nov 2023 | HK$414.2b | HK$46.3b | -HK$18,673,865,270.00 | 18.9x | -22.2x | 8.9x |
| Wed, 25 Oct 2023 | HK$383.9b | HK$44.9b | -HK$19,087,443,396.00 | 12.9x | -20.1x | 8.6x |
| Fri, 22 Sep 2023 | HK$412.0b | HK$44.9b | -HK$18,904,276,417.00 | 16.5x | -21.8x | 9.2x |
| Sun, 20 Aug 2023 | HK$375.5b | HK$35.8b | -HK$22,939,946,336.00 | 17x | -16.4x | 10.5x |
| Tue, 18 Jul 2023 | HK$411.8b | HK$35.6b | -HK$23,402,891,725.00 | 26x | -17.6x | 11.6x |
| Thu, 15 Jun 2023 | HK$399.1b | HK$35.6b | -HK$23,469,426,477.00 | 25.8x | -17x | 11.2x |
| Sat, 13 May 2023 | HK$442.5b | HK$36.5b | -HK$24,129,908,955.00 | 16.8x | -18.3x | 12.1x |
| Mon, 10 Apr 2023 | HK$442.1b | HK$37.1b | -HK$24,186,857,438.00 | 12.2x | -18.3x | 11.9x |
| Wed, 08 Mar 2023 | HK$413.3b | HK$33.2b | -HK$36,035,759,688.00 | 23.4x | -11.5x | 12.5x |
| Fri, 03 Feb 2023 | HK$481.4b | HK$35.2b | -HK$35,599,902,968.00 | 31.2x | -13.5x | 13.7x |
| Sun, 01 Jan 2023 | HK$412.7b | HK$34.3b | -HK$34,598,534,453.00 | 27.4x | -11.9x | 12x |
| Tue, 29 Nov 2022 | HK$352.5b | HK$33.0b | -HK$33,145,211,467.00 | 20.5x | -10.6x | 10.7x |
| Thu, 27 Oct 2022 | HK$334.5b | HK$33.5b | -HK$31,892,427,785.00 | 17.5x | -10.5x | 10x |
| Sat, 24 Sep 2022 | HK$283.7b | HK$33.8b | -HK$33,117,775,427.00 | 20.3x | -8.6x | 8.4x |
| Mon, 22 Aug 2022 | HK$325.5b | HK$33.5b | -HK$45,624,035,606.00 | 11.9x | -7.1x | 9.7x |
Price to Earnings Ratio
-7.1x
Current Industry PE
- Investors are optimistic on the Hong Kong Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 9.3x is lower than the industry's current PS ratio of 15.9x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 24% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 1.99% | |
| Healthcare | 4.60% | |
| Biotech | 6.75% | |
| Biotech | 6.75% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 9995 RemeGen | HK$77.45 | 28.0% +HK$9.4b | 441.6% | PS20.6x | |
| 1801 Innovent Biologics | HK$96.00 | 5.0% +HK$7.9b | 129.7% | PS16x | |
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$433.60 | 8.5% +HK$7.7b | 181.7% | PS46.9x | |
| 9926 Akeso | HK$164.20 | 4.3% +HK$6.1b | 267.3% | PS63.4x | |
| 1877 Shanghai Junshi Biosciences | HK$32.44 | 18.9% +HK$5.3b | 180.1% | PS14.7x |